A Randomized Study of Comparison of Intravenous Dexmedetomidine and Intravenous Esmolol to Attenuate the Cardiovascular Responses to Laryngoscopy and Endotracheal Intubation

By Ninad Deepak Chodankar & Bhagyashree Shivde

Abstract- Design: Prospective, Randomized, controlled study.

Aims: Objective is to compare the efficacy of intravenous Dexmedetomidine and Esmolol in attenuating the cardiovascular pressor responses to laryngoscopy and endotracheal intubation.

Method: Study was done on 60 adults, ASA grade I or II normotensive patients, undergoing elective surgery under general anaesthesia and willing to participate. These patients were be randomly allocated in to either group E (Esmolol) or D (Dexmedetomidine). Group ‘D’, patients were given intravenous Dexmedetomidine infusion 1 mcg/kg over 10 minutes, 3 minutes before start of laryngoscopy. Group ‘E’, patients were given intravenous Esmolol 1.5 mg/kg 2 minutes before start of laryngoscopy. All patients were premedicated, induced and intubated using Thiopentone and Succinyl Choline as per the protocol.

Keywords: laryngoscopy, intubation, Esmolol, hemodynamic, response, dexmedetomidine.

GJMR-I Classification: NLMC Code: WV 505

Strictly as per the compliance and regulations of:

© 2020. Ninad Deepak Chodankar & Bhagyashree Shivde. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
A Randomized Study of Comparison of Intravenous Dexmedetomidine and Intravenous Esmolol to Attenuate the Cardiovascular Responses to Laryngoscopy and Endotracheal Intubation

Ninad Deepak Chodankar & Bhagyashree Shivde

Abstract-Design: Prospective, Randomized, controlled study.

Aims: Objective is to compare the efficacy of intravenous Dexmedetomidine and Esmolol in attenuating the cardiovascular pressor responses to laryngoscopy and endotracheal intubation.

Method: Study was done on 60 adults, ASA grade I or II normotensive patients, undergoing elective surgery under general anaesthesia and willing to participate. These patients were be randomly allocated to either group E (Esmolol) or D (Dexmedetomidine). Group 'D', patients were given intravenous Dexmedetomidine infusion 1 mcg/kg over 10 minutes, 3 minutes before start of laryngoscopy. Group 'E', patients were given intravenous Esmolol 1.5 mg/kg 2 minutes before start of laryngoscopy. All patients were premedicated, induced and intubated using Thiopentone and Succinyl Choline as per the protocol. Heart rate (HR), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) were recorded at baseline (taken half an hour prior to anaesthesia), Before sedation, After induction but before intubation, Immediately after endotracheal intubation and Thereafter at 1, 2, 3, 4, 5 and 10 minutes.

Analysis: For quantitative data, Unpaired Student's t-test was used. For comparison of categorical variables chi-square test was used. P-values of < 0.05 will be considered significant.

Results: Immediately after intubation, Heart rate was similar in Group D and Group E, thereafter HR remained higher in Group E as compared to Group D, and difference was statistically significant.

SBP, DBP and MAP recorded was higher in Group Eas compared to Group D, and difference was statistically significant

Conclusion: We conclude that intravenous Dexmedetomidine 1ug/kg is better drug to attenuate hemodynamic response to laryngoscopy and intubation as compared to intravenous Esmolol 1.5mg/kg.

Keywords: laryngoscopy, intubation, Esmolol, hemodynamic, response, dexmedetomidine.

I. Introduction

Laryngoscopy and endotracheal intubation is accompanied with significant increases in heart rate and arterial blood pressure (1), and can lead to adverse outcome. These cardiovascular responses are transient occurring at around 30 seconds after intubation and can last up to 10 minutes (2). The sympathetic stimulation is also associated with dysrhythmias (3).

These cardiovascular responses to sympathetic stimulation although of short duration and are of little consequence in healthy individuals, but serious complications can occur in patients with underlying coronary artery disease (4) reactive airways, (5) or intracranial neuropathology (6).

These reflexes are mediated by the cardioaccelerator nerves and sympathetic system. This response includes wide-spread release of norepinephrine from adrenergic nerve terminals and secretion of epinephrine from the adrenal medulla (7).

Esmolol is an ultra-shortacting, beta-adrenergic receptor antagonist with efficacy to provide hemodynamic stability during laryngoscopy and tracheal intubation without side-effects.(8) It inhibits Beta-1 receptors of myocardium thus attenuating positive chronotropic, to very less extent it also inhibits Beta 2 receptors of smooth muscles of vascular walls thus attenuating positive inotropic effects (9)

Dexmedetomidine is an imidazole derivative and highly selective central alpha2adrenergic receptor agonist (10). Alpha-2agonists produce hyperpolarization of noradrenergic neurons and suppression of neuronal firing in the locus coeruleus leads to decreased systemic noradrenalin release results in attenuation of sympathoadrenal responses. Although mostly used as sedative during anaesthesia, it can provide hemodynamic stability during laryngoscopy and tracheal intubation (11).

II. Method

Study Population: 60 adult ASA grade I or II normotensive patients, undergoing elective surgery
under general anaesthesia and willing to participate was the study population.

Study Design: It is a prospective randomized study. The approval for the study was obtained from the Institutional Ethics Committee.

Inclusion Criteria

- Male and female of age group between 25 to 65 years. Undergoing elective surgery under general anesthesia. Weight 40 kg to 90kg. Resting systolic blood pressure less than 140 mmHg and diastolic pressure less than 90 mmHg. American Society of Anaesthesiologist Grade I and II.

Exclusion Criteria

- Ischemic heart diseases or ECG abnormalities indicating ischemic heart diseases. Patients with any overt cardiac, renal, pulmonary and liver diseases. Hypertensive patients. Any Patients with history of dyspnoea on exertion of grade III or more as per NYHA guidelines. Obesity (weight more than 90kg). Pregnancy. ASA grade III or IV patients. Anticipated difficult intubation. Any contraindication of Dexmedetomidine and Esmolol.

a) Methodology

Pre-Operative Investigations and Assessment

A preoperative evaluation was carried out in all patients with demographic data like age, gender, weight and detailed clinical history, physical examination including, associated medical co-morbidities, and current medications. Blood pressure was measured at three occasions at least 1 hour apart to confirm that it fulfils the selection criteria. All routine and relevant investigations such as complete blood count, renal function test (serum electrolytes, serum creatinine, and blood urea levels), urine routine and microscopy, electrocardiogram, chest X-ray were carried out for all patients. The factors indicating difficult intubation on clinical examination were ruled out.

Pre-Operative Management

All patients received Tablet Pantoprazole 40 mg at night before surgery and 3 hours before surgery and Tablet Alprazolam 0.5 mg was given night before surgery. A 20G intravenous cannula was secured on non-dominant hand in appropriate vein in wards and intravenous fluid Ringers Lactate 500 ml as maintenance was started about 3 hours prior to surgery. About one hour prior to surgery, baseline readings were taken for pulse rate and blood pressures (Systolic, Diastolic and Mean) and were considered as preoperative baseline reading.

These patients were be randomly allocated in to either group E (Esmolol) or D (Dexmedetomidine). Once group was decided, blinding was not maintained.

In Operation Theatre

In the preoperative area, monitoring of hemodynamic parameters such as Heart Rate, Non-invasive blood pressure monitoring (NIBP), oxygen saturation (SpO2) and Electrocardiography (ECG) was done. Five ECG leads were placed on chest and Lead II, Lead aVL and Lead V were continuously observed on monitor. In operation theatre monitoring of these parameters were continued. All the 3 groups received sedation with Intravenous Midazolam 0.02 mg/kg and Fentanyl 2 mcg/kg about 15 minutes before induction. Preoxygenation with 100% oxygen by using facemask in closed circuit to achieve oxygen saturation (SpO2) of 98 - 99% was done.

- For Group ‘D’, patients were given intravenous Dexmedetomidine infusion 1 mcg/kg over 10 minutes, 3 minutes before start of laryngoscopy.
- For Group ‘E’, patients were given intravenous Esmolol 1.5 mg/kg 2 minutes before start of laryngoscopy.

Induction of anaesthesia was done with Intravenous Thiopentone 5mg/kg body weight given slowly till loss of eyelash reflex is seen. Then intravenous Succinylcholine was given in dose of 2 mg/kg. Then facemask ventilation was done till twitches disappears and adequate relaxation obtained. Direct laryngoscopy was conducted by the same anaesthesia consultant for all cases, using standard McIntosh blade and an appropriate size cuffed endotracheal tube lubricated with non-anaesthetic jelly and was inserted in single attempt and cuff will be immediately inflated with air to a pressure of 25 cm of water.

After confirming bilateral equality of air entry in lungs by auscultation, the endotracheal tube was secured with the adhesive tape. Ventilation was done by IPPV on ventilator. Ventilatory setting was set to provide tidal volume of 8-10 mg/kg and respiratory rate 14/minute for 10 minutes. No noxious stimulus or surgical incision was applied over 10 minutes after intubation. Supine position was maintained. Anaesthesia was maintained using 50% nitrous oxide and 50% oxygen with Isoflurane (MAC-1.0). Hemodynamic parameters were monitored as follows: Heart rate (HR), Systolic blood pressure (SBP), Diastolic blood pressure (DBP), Mean Arterial Pressure (MAP) by non-invasive technique.

The intervals for these measurements were:

1. Baseline (taken half an hour prior to anaesthesia)
2. Before sedation
3. After induction but before intubation
4. Immediately after intubation
5. Thereafter at 1, 2, 3, 4, 5 and 10 minutes.

After this monitoring for 10 minutes post-intubation, further operative and anaesthetic procedure were continued as per plan.
b) **Statistical methods**

- Statistical analysis was carried out with the help of SPSS (version 20) for Windows package (SPSS Science, Chicago, IL, USA). The description of the data was done in form of mean +/- SD for quantitative data while in the form of % proportion for qualitative (categorical) data. P-values of < 0.05 will be considered significant.
- For quantitative data, Unpaired Student’s t-test was used to test statistical significance of difference between two independent group means.
- For comparison of categorical variables chi-square test was used.

### III. RESULTS

Comparison of patient variables such as age, gender and weight shows that there is no statistically significant demographical difference between group D and E. (Table 1)

#### Table No. 1: Comparison of Patient variables

| Variables | GROUPS | p-Value |
|-----------|--------|---------|
| Age       | Group D: 34.8 ± 12.494 | Group E: 37.6 ± 12.653 | 0.392 |
| Weight    | 65.4 ± 9.103 | 63.93 ± 7.856 | 0.506 |
| Gender    | Male: 19 | Male: 19 | 1.000 |
|           | Female: 11 | Female: 11 |         |

Heart rate was lower in Group D as compared to Group E. There was no statistically significant difference at baseline, before sedation, after induction or immediately after intubation. Thereafter heart rate was statistically significant lower in group D. (Table 2)

#### Table No. 2: Intergroup Comparison of mean Heart Rate between Group D and E

| Time          | Group D | Group E | p-Value |
|---------------|---------|---------|---------|
| Baseline      | 80.60 ± 11.267 | 80.63 ± 6.891 | 0.990 |
| Before Sedation | 80.57 ± 11.392 | 81.60 ± 7.233 | 0.689 |
| After Induction | 79.67 ± 11.081 | 79.33 ± 10.410 | 0.912 |
| Immediately after Intubation | 84.53 ± 10.679 | 88.67 ± 7.747 | 0.113 |
| 1 min         | 82.53 ± 9.365 | 88.77 ± 8.016 | 0.017* |
| 2 mins        | 80.87 ± 9.566 | 87.53 ± 7.519 | 0.014* |
| 3 mins        | 79.71 ± 9.158 | 86.53 ± 7.615 | 0.005* |
| 4 mins        | 78.13 ± 9.213 | 84.37 ± 7.308 | 0.014* |
| 5 mins        | 76.97 ± 9.427 | 82.73 ± 7.759 | 0.024* |
| 10 mins       | 75.23 ± 9.957 | 80.93 ± 7.843 | 0.030* |

*Statistically significant

SBP was lower in Group D as compared to Group E. There was no statistically significant difference at baseline, before sedation or after induction. Thereafter SBP was statistically significant lower in group D. (Table 3)
Table No. 3: Intergroup Comparison of mean Systolic Blood Pressure between Group D and E

|                  | Group D (Mean ± SD) | Group E (Mean ± SD) | p-Value | Group D vs E |
|------------------|---------------------|---------------------|---------|--------------|
| Baseline         | 121.33 ± 9.260      | 120.80 ± 9.368      | 0.807   |              |
| Before Sedation  | 119.90 ± 9.437      | 119.93 ± 9.584      | 0.989   |              |
| After Induction  | 121.50 ± 9.332      | 117.07 ± 8.998      | 0.067   |              |
| Immediately after Intubation | 124.50 ± 9.569 | 155.07 ± 12.086 | 0.000* |              |
| 1 min            | 121.43 ± 8.912      | 150.73 ± 10.696     | 0.000*  |              |
| 2 mins           | 118.33 ± 8.636      | 145.53 ± 9.912      | 0.000*  |              |
| 3 mins           | 117.10 ± 8.385      | 141.00 ± 9.040      | 0.000*  |              |
| 4 mins           | 114.87 ± 8.386      | 133.53 ± 8.460      | 0.000*  |              |
| 5 mins           | 112.67 ± 8.547      | 126.27 ± 9.752      | 0.000*  |              |
| 10 mins          | 111.30 ± 8.567      | 120.40 ± 8.869      | 0.000*  |              |

*statistically significant

DBP was lower in Group D as compared to Group E. There was no statistically significant difference at baseline, before sedation or after induction. Thereafter DBP was statistically significant lower in group D except at 10 minutes after intubation, where difference was not statistically significant. (Table 4)

Table No. 4: Intergroup Comparison of mean Diastolic Blood Pressure between Group D and E

|                  | Group D (Mean ± SD) | Group E (Mean ± SD) | p-Value | Group D vs E |
|------------------|---------------------|---------------------|---------|--------------|
| Baseline         | 77.73 ± 8.832       | 76.93 ± 9.927       | 0.783   |              |
| Before Sedation  | 78.60 ± 7.445       | 76.83 ± 9.745       | 0.498   |              |
| After Induction  | 78.03 ± 7.337       | 76.43 ± 11.352      | 0.566   |              |
| Immediately after Intubation | 79.80 ± 7.513 | 89.53 ± 8.016 | 0.000* |              |
| 1 min            | 79.03 ± 7.712       | 86.37 ± 8.869       | 0.004*  |              |
| 2 mins           | 77.37 ± 7.513       | 84.23 ± 9.591       | 0.008*  |              |
| 3 mins           | 75.47 ± 7.628       | 84.23 ± 9.591       | 0.006*  |              |
| 4 mins           | 73.60 ± 7.686       | 80.63 ± 9.608       | 0.009*  |              |
| 5 mins           | 72.00 ± 8.077       | 77.90 ± 9.532       | 0.033*  |              |
| 10 mins          | 69.73 ± 8.292       | 73.80 ± 8.919       | 0.121   |              |

*statistically significant

MAP was lower in Group D as compared to Group E. There was no statistically significant difference at baseline, before sedation or after induction. Thereafter DBP was statistically significant lower in group D except at 10 minutes after intubation, where difference was not statistically significant. (Table 5)
**Table 5:** Intergroup Comparison of mean MAP between Group D and E

| Time                  | Group D          | Group E          | p-Value  |
|-----------------------|------------------|------------------|----------|
| Mean ± SD             | Mean ± SD        | Group D vs E     |
| Baseline              | 92.50 ± 12.857   | 91.53 ± 6.485    | 0.738    |
| Before Sedation       | 93.87 ± 12.005   | 91.60 ± 6.431    | 0.468    |
| After Induction       | 96.17 ± 11.308   | 91.33 ± 6.787    | 0.084    |
| Immediately after Intubation | 97.37 ± 10.227 | 109.80 ± 7.911 | 0.000*   |
| 1 min                 | 95.83 ± 9.706    | 106.00 ± 8.383   | 0.000*   |
| 2 mins                | 93.00 ± 9.798    | 102.97 ± 8.336   | 0.000*   |
| 3 mins                | 90.67 ± 9.185    | 99.63 ± 7.792    | 0.000*   |
| 4 mins                | 89.00 ± 9.620    | 97.00 ± 7.297    | 0.001*   |
| 5 mins                | 87.03 ± 9.301    | 92.43 ± 6.951    | 0.012*   |
| 10 mins               | 85.63 ± 9.338    | 88.57 ± 7.055    | 0.174    |

*statistically significant

**Graph No. 1:** Comparison of Mean Heart Rate

**Graph No. 2:** Comparison of Mean SBP
IV. Discussion

There is well recognised, hemodynamic response which is characterized by tachycardia and hypertension due to manipulation in the area of the larynx, during laryngoscopy and endotracheal intubation. Stimulation of mechanoreceptors in the pharyngeal wall, epiglottis and vocal cords, is thought to be the cause for this hemodynamic response.

Cardiovascular pressor response following laryngoscopy and tracheal intubation has been investigated extensively for a long time and reported these changes. (12). Myocardial ischemia might occur during the induction-intubation sequence in patients with coronary artery disease. Intraoperative ischemia has been associated with a high rate of perioperative myocardial infarction. (13) During procedure like direct laryngoscopy involving severe sympathetic stimuli prevention of tachycardia, hypertension and rise in total oxygen consumption may prove beneficial in patients with limited cardiac reserve (14).

Esmolol is effective, in a dose-dependent manner, in the attenuation of the sympathomimetic response to laryngoscopy and intubation. Shrestha et al (15) noted that doses of Esmolol higher than 1.5 mg/kg did not completely prevent the pressor response to laryngoscopy and intubation. Sum et al (16) has also found a similar effect in addition to increase in intracranial pressure.

Dyson et al (17) noted that Esmolol in doses 1 mg/kg was insufficient to control the increase in systolic blood pressure compared to 1.5 mg/kg and 2 mg/kg which controlled both systolic blood pressure and heart rate, but 2 mg/kg dose produced significant decreases in systolic blood pressure.

Miller et al (18) in their study have reported that 100 mg of single bolus dose of Esmolol was effective for controlling the hemodynamic response to tracheal intubation in a Canadian multicentre trial.

Study done by Sanjeev Singh et al (19) comparing Esmolol also showed significant increase in Heart Rate after intubation and remained significantly high at 3 and 5 mins. They also found increase in SBP, DBP and MAP from the baseline in after Esmolol at 1 min with onward decreases at 3 and 5 min respectively after intubation. Kindler et al (20) also found that Esmolol administration before laryngoscopy was insufficient to control HR and SBP after intubation. Oxorn et al (21) concluded that Esmolol in bolus doses of 100 mg and 200 mg affects solely the chronotropic response in a significant manner, more so than hypertensive response.

Dexmedetomidine is a highly selective and specific alpha two adrenergic agonist which produces its action by decreasing the catecholamine release from locus coeruleus in the brain. It decreases the cerebral blood flow (CBF) while preserving the CBF-cerebral...
metabolic rate coupling, decreases intracranial pressure. (22,23,24) It also decreases sympathetic tone and their preoperative use has been shown to blunt the hemodynamic responses to laryngoscopy and intubation. (25)

Sagiroglu et al. concluded that the overall control of hemodynamic responses to tracheal intubation were better with Dexmedetomidine 1 μg/kg as compared to Dexmedetomidine 0.5 μg/kg (26). Laha et al (27) in their study compared Dexmedetomidine 1 μg/kg with control and concluded that Dexmedetomidine effectively blunted the hemodynamic responses during laryngoscopy, and reduced anaesthetic requirements.

Reddy et al (28) observed that Esmolol was not as effective as Dexmedetomidine in attenuating the hypertensive response to tracheal intubation. In fact, after use of Esmolol for intubation a significant increase in SBP was observed and compared to Dexmedetomidine the increase in SBP was greater and more significant in this study.

Srivastava et al (29) also found Systolic blood pressure values were statistically significantly lower in the Dexmedetomidine after induction and all time observation of intubation, when compared with Esmolol to the baseline values. They also observed statistical significant increase in Blood pressure after intubation at 1, 2 and 3 min only after intubation. Although Esmolol was considered to have significant effect on both tachycardia and hypertensive response following ET intubation,

Unlike our study, Liu et al (30) who used Esmolol infusion to control hemodynamic responses associated with intubation, found significant decreases in a SBP prior to induction and post-intubation, compared to the placebo group. This could be because in their study patients received infusion rather than bolus like our study.

In present study, pretreatment with Esmolol 1.5 mg/kg attenuated, but did not totally obtund, the cardiovascular response to tracheal intubation after induction of anesthesia and these findings are similar with previous studies. β-adrenoeceptor blockade minimizes increase in HR and myocardial contractility by attenuating the positive chronotropic and inotropic effects of increased adrenergic activity. But it failed to effectively attenuate hypertensive response to intubation.

Our study demonstrated that the use of Dexmedetomidine was more effective than Esmolol in decreasing the cardiovascular responses to laryngoscopy and intubation.

V. Conclusion

In Normotensive patients requiring general anesthesia with intubation, after induction with Fentanyl and Thiopentone, and Succinylcholine as muscle relaxant, we found that intravenous Dexmedetomidine 1μg/kg is better drug to attenuate hemodynamic response to laryngoscopy and intubation as compared to intravenous Esmolol 1.5mg/kg.

Acknowledgements

I express my sincere thanks to all my patients who made my research possible and meaningful.

Declarations

Funding: None Required

Conflict of interest: None

Ethical approval: Approval was obtained from hospital’s ethical and scientific committee.

References Références Referencias

1. Koji T, Kengo N, Massaki H. Cardiovascular response to rapid anesthesia induction and endotracheal intubation. Anaesthesia and Analgesia. 1964; 43:201-208.
2. Stoelting RK, Peterson C. Circulatory changes during laryngoscopy and tracheal intubation influence of duration of laryngoscopy with or without prior lidocaine. Anaesthesiology. 1972; 47: 381-383.
3. Burstein CL, LoPinto FJ, Newman W. Electrocardiographic studies during endotracheal intubation. I. Effects during usual routine technics. Anesthesiology. 1950 Mar; 11(2):224-37.
4. Loeb HS, Saudye A, Croke RP. Effects of pharmacologically induced hypertension on myocardial ischemia and coronary hemodynamics in patients with fixed coronary obstruction. Circulation. 1978; 57:41-46.
5. Dohi S, Gold M. Pulmonary mechanics during general anesthesia. Br J Anaesth. 1979; 51: 205–213.
6. Shapiro HM, Wyte SR, Harris AB. Acute intraoperative intracranial hypertension in neurosurgical patients: Mechanical and pharmacologic factors. Anesthesiology. 1972; 37:399–405.
7. Hassan HG, el-Sharkawy TY, Renck H. Hemodynamic and catecholamine responses to laryngoscopy with vs. without endo-tracheal intubation. ActaAnaesthesiol Scand. 1991; 35:442–447.
8. Louizos AA, Hatzilia SJ, Davilis DI, Samanta EG, Georgiou LG. Administration of esmolol in microlaryngeal surgery for blunting the hemodynamic response during laryngoscopy and...
A Randomized Study of Comparison of Intravenous Dexmedetomidine and Intravenous Esmolol to Attenuate the Cardiovascular Responses to Laryngoscopy and Endotracheal Intubation

tracheal intubation in cigarette smokers. Ann OtolRhinolLaryngol. 2007; 116:107-11.
9. Menkhaus PG, Reves JG, Kissinl, Alvis JM, Govier AV, Samuelson PN, Lell WA, Henling CE, Bradley E. Cardiovascular Effects of Esmolol in Anesthetized Humans. Anesthesia & Analgesia. 1989; 64(3): 327-34.
10. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists- Their pharmacology and therapeutic role. Anaesthesia. 1999; 54:146-65.
11. Grewal A. Dexmedetomidine: New avenues. J AnaesthesiolClinPharmacol. 2011; 27:297-302.
12. King BD, Harris LC Jr, Greifenstein FE, Elder JD Jr, Dripps RD. Reflex circulatory responses to direct laryngoscopy and tracheal intubation performed during general anesthesia. Anesthesiology 1951; 12:556-66.
13. Chraemmer-Jørgensen B, Høiland-Carlsen PF, Marving J, Christensen V. Lack of effect of intravenous lidocaine on hemodynamic responses to rapid sequence induction of general anesthesia: A double-blind controlled clinical trial. AnesthAnalg. 1986; 65:1037–41.
14. Mikawa K, Nishina K, Maekawa N, Obara H. Comparison of Nicardipine, Diltiazem and Verapamil for controlling the cardiovascular responses to tracheal intubation. British Journal of Anaesthesia. 1996; 76: 221 – 226.
15. Shrestha GS, Marhatta MN, Amatya R. Use of gabapentin, esmolol or their combination to attenuate haemodynamic response to laryngoscopy and intubation. Kathmandu Univ Med J. 2011; 9:238–43.
16. Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM. Kinetics of esmolol, an ultra-short acting beta blocker, and of its major metabolite. ClinPharmacolTher. 1983; 34:427-34.
17. Dyson A, Isaac PA, Pennant JH, Giesecke AH, Lipton JM. Esmolol Attenuates Cardiovascular Responses to Extubation. Anesthesia & Analgesia 1990, 71:675-8.
18. Miller DR, Martineau RJ, Wynands JE, Hill J. Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: The Canadian Multicentre Trial. Can J Anaesth 1991; 38:849-58.
19. Singh S, Laing EF, Owiredu WK, Singh A. Comparison of esmolol and lidocaine for attenuation of cardiovascular stress response to laryngoscopy and endotracheal intubation in a Ghanaian population. Anesth Essays Res. 2013 Jan-Apr; 7(1): 83–88.
20. Kindler CH, Schumacher PG, Schneider MC, Urwyler A. Effects of intravenous lidocaine and/or esmolol on hemodynamic responses to laryngoscopy and intubation: A double-blind, controlled clinical trial. Journal of Clinical Anesthesia. 1996 September; 8(6):491–496.
21. Oxorn D, Knox JW, Hill J. Bolus doses of esmolol for the prevention of perioperative hypertension and tachycardia. Can J Anaesth 1990; 37:206-9.
22. Drummond JC, Dao AV, Roth DM, Cheng CR, Atwater Bl, Minokadeh A. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology. 2008; 108:225–32.
23. Ohata H, Iida H, Dohi S, Watanabe Y. Intravenous dexmedetomidine inhibits cerebrovascular dilation induced by isoflurane and sevoflurane in dogs. AnesthAnalg. 1999; 89:370–7.
24. Jolkonen J, Puurunen K, Koistinaho J, Kauppinen R, Haapalinna A, Nieminen L, et al. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol. 1999; 372:31–6.
25. Aantaa R, Jalonen J. Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient. Eur J Anaesthesiol. 2006; 23:361–72.
26. Sagiroglu AE, Celik M, Orhon Z, Yüzer S, Sen B. Different doses of Dexmedetomidine on controlling hemodynamic responses to tracheal intubation. The Internet Journal of Anesthesiology. 2010; 27(2): [ispub.com/IJA/27/2/10323].
27. Laha A, Ghosh S, Sarkar S. Attenuation of sympathoadrenal responses and anesthetic requirement by dexmedetomidine. Anesth Essays Res. 2013; 7:65–70.
28. Reddy SV, Balaji D, Ahmed SN. Dexmedetomidine versus esmolol to attenuate the hemodynamic response to laryngoscopy and tracheal intubation: A randomized double-blind clinical study. Int J Appl Basic Med Res. 2014 Jul; 4(2):95-100.
29. Srivastava VK, Agrawal S, Gautam SK, Ahmed M, Sharma S,Kumar R, Comparative evaluation of esmolol and dexmedetomidine for attenuation of sympathomimetic response to laryngoscopy and intubation in neurological patients. Journal of Anaesthesiology Clinical Pharmacology. 2015 31 (2):186-190.
30. Liu PL, Gatt S, Gugino LD, Mallampati SR, Covino BG. Esmolol for control of increases in heart rate and blood pressure during tracheal intubation after thiopentone and succinylcholine. Can AnaesthSoc J 1986; 33:556-62.